Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2011-07-05
2011-07-05
Raghu, Ganapathirama (Department: 1652)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S094600, C435S235100, C514S001100, C514S04400A
Reexamination Certificate
active
07972593
ABSTRACT:
This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability in the blood, by attaching multiple copies of acid amino acid peptides. One preferred embodiment of the invention relates to endowing an adeno-associated virus (AAV) vector with the ability to target bone-tissue in vivo and improve its stability, by the addition of multiple acidic amino acid peptides attached to the capsid of the viral vector.
REFERENCES:
patent: 6455495 (2002-09-01), Orgel et al.
patent: 6491907 (2002-12-01), Rabinowitz et al.
patent: 6582692 (2003-06-01), Podsakoff et al.
patent: 2002/0169125 (2002-11-01), Leung et al.
patent: 2006/0014687 (2006-01-01), Crine et al.
patent: 2852127 (1999-01-01), None
patent: 2000-327583 (2000-11-01), None
patent: 2002-3402 (2002-01-01), None
patent: 95/09611 (1995-04-01), None
patent: 9509611 (1995-04-01), None
patent: 99/33957 (1999-07-01), None
patent: 2005121344 (2005-12-01), None
Broun et al., Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids. Science, 1998, vol. 282: 1315-1317.
Chica et al., Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design. Curr. Opi. Biotechnol., 2005, vol. 16: 378-384.
Devos et al., Practical limits of function prediction. Proteins: Structure, Function, and Genetics. 2000, vol. 41: 98-107.
Kisselev L., Polypeptide release factors in prokaryotes and eukaryotes: same function, different structure. Structure, 2002, vol. 10: 8-9.
Sen et al., Developments in directed evolution for improving enzyme functions. Appl. Biochem. Biotechnol., 2007, vol. 143: 212-223.
Tomatsu et al., Development of MPS IVA mouse (GaIns(tmhC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase. Human Mol. Genetics, 2005, vol. 14 (22): 3321-3335.
Whisstock et al., Prediction of protein function from protein sequence. Q. Rev. Biophysics., 2003, vol. 36 (3): 307-340.
Wishart et al., A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. J. Biol. Chem., 1995, vol. 270(45): 26782-26785.
Witkowski et al., Conversion of b-ketoacyl synthase to a Malonyl Decarboxylase by replacement of the active cysteine with glutamine. Biochemistry, 1999, vol. 38: 11643-11650.
Achord et al., Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15 (1978) 269-278.
Altarescu, et al., The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J. Pediatr. 138 (2001) 539-547.
Anderson et al., Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am. J. Pathol. 164 (2004) 841-847.
Anderson et al., Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals. Am. J. Pathol. 151 (1997) 1555-1561.
Barranger et al., Lessons learned from the development of enzyme therapy for Gaucher disease. J. Inherit. Metab. Dis. 24 (2001) 89-96.
Barton, et al.; Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease., Proc. Natl. Acad. Sci. USA (1990) 87, 1913-1916.
Barton, et al.; Replacement therapy for inherited enzyme deficiency—macrophage targeted glucocerebrosidase for gaucher's disease., N. Engl. J. Med. (1991) 324, 1464-1470.
Bernardi, “Chromatography of Proteins on Hydroxyapatite”, Methods Enzvmol 27:471-9 (1973).
Boskey et al., Matrix vesicles promote mineralization in a gelatin gel. Calcif. Tissue Int. 60 (1997) 309-315.
Boskey, Amorphous calcium phosphate: the contention of bone. J. Dent. Res. 76 (1997) 1433-1436.
Crawley et al., Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J. Clin. Invest. 97 (1996) 1864-1873.
Dunder, et al.; Enzyme replacement therapy in a mouse model of Aspartylglycosaminuria., FASEB J. (2000)14, 361-367.
Eng et al., International Collaborative Fabry Disease Study Group, Safety and efficacy of recombinant human alpha galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. 345 (2001) 9-16.
Fujisawa, et al., Acidic amino acid-rich sequences as binding sites of osteonectin to hydroxyapatite crystals. Biochimica et Biophysica Acta (1996) 1292 53-60.
Fujisawa, et al.; Attachment of Osteoblastic Cells to Hydroxyapatite Crystals by a Synthetic Peptide (Glu7-Pro-Arg-Gly-Asp-Thr) Containing two Functional Sequences of Bone Sialoprotein., Matrix Biology vol. (1997) 16/1997, pp. 21-28.
Furbish et al., Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim. Biophys. Acta. 673 (1981) 425-434.
Goldberg et al.;Binding of Bone Sialoprotein, Osteopontin and Synthetic Polypeptides to Hydroxyapatite., Connective Tissue Research. (2001) vol. 42(1), pp. 25-37.
Kakkis et al., Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344 (2001) 182-188.
Kasugai, et al., Selective Drug Delivery System to Bone: Small Peptide (Asp)6 Conjugation, (2000) J. Bone. Miner. Res. 15, 936-943.
Kauko, et al: “Type IV Mucopol Ysaccharidosis (Morquio Syndrome), Congenital Metabolic Disorder Syndromes”, Japanese Journal of Clinical Medicine, Suppl No. 2, p. 442-445 (1998).
Leone et al., Allosteric modulation of pyrophosphatase activity of rat osseous plate alkaline phosphatase by magnesium ions. Int. J. Biochem. Cell Biol. 30 (1998) 89-97.
Meyer, Can biological calcification occur in the presence of pyrophosphate? Arch. Biochem. Biophys. 15 (1984) 1-8.
Moss et al., Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. Biochem. J. 102 (1967) 53-57.
Murray, Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells. Methods Enzymol. 149 (1987) 25-42.
Narisawa et al., Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. J Pathol. 191 (2001) 125-133.
Narisawa et al., Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev. Dyn. 208 (1997) 432-446.
Nishioka et al., Enhancement of drug delivery to bone: Characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab. Jul. 2006; 88(3):244-255. Epub Apr. 17, 2006.
Niwa, et al., “Efficient Selection for High-Expression Transfectants With a Novel Eukaryotic Vector” Gene 108:193-200 (1991).
Roces, et al., Efficacy of enzyme replacement therapy in a-mannosidosis mice: a preclinical animal study. Hum. Mol. Genet. (2004), 13:1979-1988.
Rose. et al: “Primary Structure of the Human Melanoma Associated Antigen p97 (Melanotransferrin) Deduced From the MRNA Sequence” Proc. Natl Acad. Sci. USA. 83:1261-1265 (1986).
Russell et al., Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J. Clin. Invest. 50 (1971) 961-965.
Sands et al., Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J. Clin. Invest. 93 (1994) 2324-2331.
Shull et al., Enzyme replacement in a canine model of Hurler syndrome. Proc. Natl. Acad. Sci. 91 (1994) 12937-12941.
Sly et al., Beta glucuronidase deficiency: Report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis J Pediatr. (1973) 82:249-257.
Sly, et al., Active site mutant transgene confers tolerance to human b-glucuronidase without affecting the phenotype of MPS VII mice, Proc. Natl. Acad. Sci. USA (2001) 98, 2205-2210.
Stahl et al., Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and glycosidases by alveolar macrophages. Proc.
Alméciga-Diaz Carlos J.
Barrera Luis
Montaño-Suarez Adriana
Tomatsu Shunji
Bretton Randolph
Raghu Ganapathirama
Saint Louis University
The Law Office of Randolph Bretton
LandOfFree
Delivery of therapeutic agents to the bone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery of therapeutic agents to the bone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery of therapeutic agents to the bone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699579